Spots Global Cancer Trial Database for triple negative
Every month we try and update this database with for triple negative cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | NCT03911453 | Breast Cancer | Rucaparib | 21 Years - | University of Arizona | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer | NCT01289353 | Breast Cancer | Carboplatin 3D-RT or IMRT | 18 Years - | NYU Langone Health | |
| BKM120 For Triple Negative Breast Cancer | NCT01790932 | Breast Cancer | BKM120 | 18 Years - | Dana-Farber Cancer Institute | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | NCT02499367 | Breast Cancer | Nivolumab Radiation thera... Low dose doxoru... Cyclophosphamid... Cisplatin | 18 Years - | The Netherlands Cancer Institute | |
| Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | NCT02685059 | Breast Cancer | MEDI4736 (Anti ... Placebo nab-Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | German Breast Group | |
| Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | NCT01889238 | Advanced, Andro... | Enzalutamide | 18 Years - | Pfizer | |
| Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | NCT03970967 | Breast Carcinom... Metastatic Brea... Invasive Breast... Distant Metasta... | Device: Radiati... | 45 Years - | Alpha Tau Medical LTD. | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Cisplatin + RT for Triple Negative Breast Cancer | NCT01674842 | Breast Cancer | Radiation Thera... Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | NCT02732860 | Colorectal Neop... Colorectal Canc... Breast Cancer Breast Neoplasm... Ovarian Cancer Ovarian Neoplas... | Molecular Profi... | 18 Years - | University Health Network, Toronto | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | Ovarian Cancer Breast Cancer | BKM120 and Olap... BYL719 and Olap... | 18 Years - | Dana-Farber Cancer Institute | |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | NCT01421472 | ER Positive, He... Triple Negative... | MM-121 Paclitaxel | 18 Years - | Merrimack Pharmaceuticals | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | NCT03205761 | Advanced Breast... | Olaparib | 18 Years - | Spanish Breast Cancer Research Group | |
| Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer | NCT00463788 | Breast Neoplasm | cetuximab, cisp... cisplatin | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen | NCT03304756 | Triple Negative... | CAP | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | NCT06245889 | Triple Negative... | Paclitaxel Carboplatin Pembrolizumab Doxorubicin Cyclophosphamid... Olaparib Capecitabine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer | NCT06247449 | Breast Cancer | Brain imaging Analysis of cir... Testing Morbidi... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer | NCT02521363 | Breast Cancer | KIBUR MICRODEVI... anthracycline a... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Erlotinib and Metformin in Triple Negative Breast Cancer | NCT01650506 | Breast Cancer | Metformin Erlotinib | 18 Years - 79 Years | Columbia University | |
| Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer | NCT02929576 | Breast Cancer | Enzalutamide Placebo Paclitaxel | 18 Years - | Pfizer | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | NCT05491083 | Advanced Solid ... Triple Negative... | Pembrolizumab &... Pembrolizumab &... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer | NCT05302778 | Breast Cancer Metastatic Brea... Triple Negative... | 18 Years - | University of Milano Bicocca | ||
| Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | NCT05552001 | Triple Negative... Metastatic Brea... | Sacituzumab gov... | 18 Years - | UNICANCER | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) | NCT04333706 | Breast Metastatic Triple Negative Cancer Disseminated Tu... | Capecitabine Sarilumab 150mg... Sarilumab 150mg... | 18 Years - 99 Years | University of Southern California | |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 | Breast Cancer HER2-negative B... HER2-positive B... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Carboplatin paclitaxel albu... bevacizumab trastuzumab magnetic resona... therapeutic con... | 21 Years - 90 Years | University of California, Irvine | |
| Triple Negative Breast Cancer Trial | NCT00532727 | Breast Cancer | Carboplatin Docetaxel | 18 Years - | Institute of Cancer Research, United Kingdom | |
| PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | NCT06245889 | Triple Negative... | Paclitaxel Carboplatin Pembrolizumab Doxorubicin Cyclophosphamid... Olaparib Capecitabine | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer | NCT05692661 | Triple Negative... HER2-positive B... | proton plus car... | 18 Years - 80 Years | Shanghai Proton and Heavy Ion Center | |
| A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | NCT00951054 | Triple Negative... | NK012 | 18 Years - | Nippon Kayaku Co., Ltd. | |
| Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | NCT02499367 | Breast Cancer | Nivolumab Radiation thera... Low dose doxoru... Cyclophosphamid... Cisplatin | 18 Years - | The Netherlands Cancer Institute | |
| S-equol in Women With Triple Negative Breast Cancer | NCT02352025 | Breast Cancer | S-equol | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) | NCT01779479 | Primary Breast ... | Cabacitaxel Paclitaxel | 18 Years - | German Breast Group | |
| Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer | NCT02455141 | Breast Neoplasm | Epirubicin plus... Taxanes Taxanes plus Ca... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | NCT00707707 | Breast Cancer Triple Negative... Metastatic Brea... | AZD2281 Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer | NCT05169853 | Triple Negative... HER2-positive B... | 18 Years - | Ain Shams University | ||
| A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | NCT03945721 | Triple Negative... Residual Diseas... | Niraparib Radiation Thera... | 18 Years - | Massachusetts General Hospital | |
| Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer | NCT00472693 | Breast Cancer | Bevacizumab, Ab... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | NCT01074970 | Breast Cancer | Cisplatin Rucaparib Cisplatin | 18 Years - | Hoosier Cancer Research Network | |
| Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | NCT03970967 | Breast Carcinom... Metastatic Brea... Invasive Breast... Distant Metasta... | Device: Radiati... | 45 Years - | Alpha Tau Medical LTD. | |
| Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS | NCT05451784 | Metastatic Trip... | PD1+ TILs (NUMA... | 18 Years - | Fundacio Clinic Barcelona | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | NCT00777673 | Breast Cancer | Bevacizumab, na... | 18 Years - | University of Tennessee Cancer Institute | |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer | NCT04142554 | Breast Cancer Breast Neoplasm... Triple Negative... HER2-positive B... | Parsaclisib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| S-equol in Women With Triple Negative Breast Cancer | NCT02352025 | Breast Cancer | S-equol | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry | NCT02670577 | Breast Cancer | 18 Years - | Agendia | ||
| ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases | NCT02048059 | Breast Cancer Brain Metastase... | ANG1005 | 18 Years - | Angiochem Inc | |
| Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | NCT05035745 | Advanced Refrac... Advanced Triple... Metastatic Trip... | Talazoparib Selinexor | 18 Years - 99 Years | National University Hospital, Singapore | |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) | NCT04333706 | Breast Metastatic Triple Negative Cancer Disseminated Tu... | Capecitabine Sarilumab 150mg... Sarilumab 150mg... | 18 Years - 99 Years | University of Southern California | |
| Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | NCT01889238 | Advanced, Andro... | Enzalutamide | 18 Years - | Pfizer | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | NCT05552001 | Triple Negative... Metastatic Brea... | Sacituzumab gov... | 18 Years - | UNICANCER | |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | NCT01623349 | Ovarian Cancer Breast Cancer | BKM120 and Olap... BYL719 and Olap... | 18 Years - | Dana-Farber Cancer Institute | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer | NCT02521363 | Breast Cancer | KIBUR MICRODEVI... anthracycline a... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients | NCT02027376 | Advanced Breast... | LDE225 Docetaxel | 18 Years - | Spanish Breast Cancer Research Group | |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 | Breast Cancer HER2-negative B... HER2-positive B... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Carboplatin paclitaxel albu... bevacizumab trastuzumab magnetic resona... therapeutic con... | 21 Years - 90 Years | University of California, Irvine | |
| Cisplatin + RT for Triple Negative Breast Cancer | NCT01674842 | Breast Cancer | Radiation Thera... Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | NCT02802423 | Triple Negative... | BLEX 404 Oral L... | 20 Years - 70 Years | BioLite, Inc. | |
| MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer | NCT06247449 | Breast Cancer | Brain imaging Analysis of cir... Testing Morbidi... | 18 Years - | Sunnybrook Health Sciences Centre | |
| PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | NCT01074970 | Breast Cancer | Cisplatin Rucaparib Cisplatin | 18 Years - | Hoosier Cancer Research Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
